A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults

A Phase I, Randomized, Open-label, 3 or 4-period, 7-treatment, Single-dose, Two Cohort, Crossover Study to Assess the Relative Bioavailability of Laroprovstat/Rosuvastatin Fixed Combination Drug Products to the Single Therapy Products in Healthy Adults

The purpose of this study is to assess how well laroprovstat and rosuvastatin combined in a single tablet to be taken by mouth works compared with laroprovstat and rosuvastatin individual tablets taken by mouth (relative bioavailability) in healthy adults.

Study Overview

• Status: Active, not recruiting
• Conditions: Healthy Participants
• Intervention / Treatment: Drug: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1; Drug: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2; Drug: Laroprovstat Dose X STP; Drug: Rosuvastatin Dose 1 STP; Drug: Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1; Drug: Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2; Drug: Rosuvastatin Dose 2 STP

Detailed Description

This is a randomized, open-label, 3 or 4-period, single-dose, two-cohort, multi-center, crossover study. The study will comprise of a screening period (21 Days), 3 or 4 treatment periods (depending on cohort assignment) and washout period (14 Days, starting after dosing on Study Day 1 of a given treatment period). Each treatment period consists of dosing on Day 1; any subsequent treatment period will not start sooner than 14 days following dosing in the previous treatment period.

• Study Type: Interventional
• Enrollment (Actual): 44
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • California
    • Glendale, California, United States, 91206
      • Research Site
  • Maryland
    • Brooklyn, Maryland, United States, 21225
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Provision of signed and dated, written informed consent prior to any study-specific procedures.
• Healthy male and female participants aged 18 to 55 years (inclusive) with suitable veins for cannulation or repeated venipuncture.
• All females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit.
• Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception, in addition to a barrier method, to avoid pregnancy from the time of first administration of study intervention until 10 days after discharge from the study site.
• Females of non-childbearing potential must be confirmed at the Screening Visit by checking if they are postmenopausal [amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) levels in the postmenopausal range] or by documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion.
• Have a body mass index between 18 and 30 kg/m2 inclusive and weigh at least 50 kg.

Exclusion Criteria:

• History of any clinically important disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
• History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
• Any prior gastrointestinal surgery which may affect absorption, example (eg), gastric bypass or resection.
• Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention.
• Asian origin.

• Any laboratory values with the following deviations at the Screening Visit or on admission to the study site. Abnormal values may be repeated once at the discretion of the investigator:

  • ALT > upper limit of normal (ULN).
  • AST > ULN.
  • TBL > ULN.
  • Estimated glomerular filtration rate < 90 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation.
  • Hemoglobin < lower limit normal (LLN).
  • Creatine kinase > 5 × ULN.
• Inadequately treated hypothyroidism defined as TSH > 1.5 × ULN at screening or participants whose thyroid replacement therapy was initiated or modified within the last 3 months prior to screening.
• Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results other than those listed above, at screening and/or admission to the study site, as judged by the investigator. Abnormal values may be repeated once at the discretion of the investigator.
• Any positive result on screening for serum Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis C virus (HCV), or Human immunodeficiency virus (HIV).

• Abnormal vital signs, after 10 minutes supine rest, at the Screening Visit and/or admission to the study site, defined as any of the following. Abnormal values may be repeated once (one triplicate measurement) at the discretion of the investigator:

  • Systolic Blood pressure (BP) < 90 mmHg or ≥ 140 mmHg.
  • Diastolic BP < 50 mmHg or ≥ 90 mmHg.
  • Pulse rate < 45 or > 90 beats per minute (bpm).
• Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening and/or admission to the study site, as judged by the investigator. Abnormal values may be repeated once at the discretion of the investigator.
• Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the previous 3 months prior to screening.
• Known or suspected history of alcohol or drug abuse or excessive intake of alcohol as judged by the investigator in the last one year.
• Positive screen for drugs of abuse, alcohol, or cotinine at screening or on each admission to the study site.
• History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to laroprovastat or rosuvastatin.
• Excessive intake of caffeine-containing drinks or food (eg, coffee, tea, chocolate) defined as the regular consumption of more than 500 mg of caffeine per day (eg, > 5 cups of coffee [one cup ~100 mg caffeine]; one cup of tea ~30 mg caffeine) or would likely be unable to refrain from the use of caffeine-containing beverages during confinement at the study site.
• Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks prior to the first administration of study intervention.
• Use of any prescribed or nonprescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, intake of > 3 × daily recommended levels of vitamins and minerals during the 2 weeks prior to the first administration of study intervention or longer if the medication has a long half-life. Hormonal contraceptives (for females of childbearing potential) are allowed.
• Treatment with any lipid lowering therapy or laroprovastat within the 3 months prior to the Screening Visit.
• Treatment with drugs for reduction or inhibition of Proprotein convertase subtilisin/kexin type 9 (PCSK9) within the last 12 months prior to the Screening Visit (approved or investigational and apart from laroprovstat).
• Current or previous administration of inclisiran.
• Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.
• Has received any Investigational Medicinal Product (IMP-defined as a compound which has not been approved for marketing) within 30 days or 5 half-lives (whichever is longest) of the first administration of study intervention in this study.
• Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
• Judgment by the investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.
• Participants who have medical dietary restrictions or are unable/unwilling to comply with the meals provided in the unit during the stay at the study site.
• Participants who cannot communicate reliably with the investigator.
• Vulnerable participants, eg, kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

7

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1 Treatment A; Participants will receive a single oral Fixed Combination Drug Product (FCDP) test formulation 1 of Dose X laroprovstat/Dose 1 rosuvastatin following an overnight fast.	Drug: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1; Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1 will be administered as an oral tablet in the morning on Day 1 of a given treatment period.
Experimental: Cohort 1 Treatment B; Participants will receive a single oral FCDP test formulation 2 of Dose X laroprovstat/Dose 1 rosuvastatin following an overnight fast.	Drug: Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2; Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2 will be administered as an oral tablet in the morning on Day 1 of a given treatment period.
Experimental: Cohort 1 Treatment C; Participants will receive a single oral Dose X laroprovstat and a single oral Dose 1 rosuvastatin as Single Therapy Product (STP) reference formulations following an overnight fast.	Drug: Laroprovstat Dose X STP; Laroprovstat Dose X STP will be administered as an oral tablet in the morning on Day 1 of a given treatment period.; Drug: Rosuvastatin Dose 1 STP; Rosuvastatin Dose 1 STP will be administered as an oral tablet in the morning on Day 1 of a given treatment period.
Experimental: Cohort 2 Treatment D; Participants will receive a single oral FCDP test formulation 1 of Dose X laroprovstat/Dose 2 rosuvastatin following an overnight fast.	Drug: Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1; Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1 will be administered as an oral tablet in the morning on Day 1 of a given treatment period.
Experimental: Cohort 2 Treatment E; Participants will receive a single oral FCDP test formulation 2 of Dose X laroprovstat/Dose 2 rosuvastatin following an overnight fast.	Drug: Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2; Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2 will be administered as an oral tablet in the morning on Day 1 of a given treatment period.
Experimental: Cohort 2 Treatment F; Participants will receive a single oral Dose X laroprovstat and a single oral Dose 2 rosuvastatin as STP reference formulations following an overnight fast.	Drug: Laroprovstat Dose X STP; Laroprovstat Dose X STP will be administered as an oral tablet in the morning on Day 1 of a given treatment period.; Drug: Rosuvastatin Dose 2 STP; Rosuvastatin Dose 2 STP will be administered as an oral tablet in the morning on Day 1 of a given treatment period.
Experimental: Cohort 2 Treatment G; Participants will receive a single oral FCDP test formulation 1 of Dose X laroprovstat/Dose 2 rosuvastatin in a fed state.	Drug: Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1; Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1 will be administered as an oral tablet in the morning on Day 1 of a given treatment period.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under concentration time curve from time 0 to infinity (AUCinf)	To evaluate the relative bioavailability between the FCDP test formulation 1 and the STPs of laroprovstat and rosuvastatin across the planned rosuvastatin dose range, Dose 1 (Cohort 1) to Dose 2 (Cohort 2)	At predefined intervals from Day 1 to Day 11
Area under concentration curve from time 0 to the last quantifiable concentration (AUClast)	To evaluate the relative bioavailability between the FCDP test formulation 1 and the STPs of laroprovstat and rosuvastatin across the planned rosuvastatin dose range, Dose 1 (Cohort 1) to Dose 2 (Cohort 2).	At predefined intervals from Day 1 to Day 11
Maximum observed drug concentration (Cmax)	To evaluate the relative bioavailability between the FCDP test formulation 1 and the STPs of laroprovstat and rosuvastatin across the planned rosuvastatin dose range, Dose 1 (Cohort 1) to Dose 2 (Cohort 2)	At predefined intervals from Day 1 to Day 11

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Terminal rate constant (λz)	To examine the PK profiles of laroprovstat and rosuvastatin when administered as FCDP test formulation 1 or STPs.	At predefined intervals from Day 1 to Day 11
Time to reach maximum observed concentration (tmax)	To examine the PK profiles of laroprovstat and rosuvastatin when administered as FCDP test formulation 1 or STPs.	At predefined intervals from Day 1 to Day 11
Terminal elimination half life (t1/2λz)	To examine the PK profiles of laroprovstat and rosuvastatin when administered as FCDP test formulation 1 or STPs.	At predefined intervals from Day 1 to Day 11
Apparent total body clearance (CL/F)	To examine the PK profiles of laroprovstat and rosuvastatin when administered as FCDP test formulation 1 or STPs.	At predefined intervals from Day 1 to Day 11
Apparent volume of distribution based on the terminal phase (V/F)	To examine the PK profiles of laroprovstat and rosuvastatin when administered as FCDP test formulation 1 or STPs.	At predefined intervals from Day 1 to Day 11
AUCinf	To examine the effect on the PK profiles of laroprovstat and rosuvastatin when administered as an FCDP test formulation 1 with high fat meal compared to when administered as an FCDP test formulation 1 in the fasted state.	At predefined intervals from Day 1 to Day 11
AUClast	To examine the effect on the PK profiles of laroprovstat and rosuvastatin when administered as an FCDP test formulation 1 with high fat meal compared to when administered as an FCDP test formulation 1 in the fasted state.	At predefined intervals from Day 1 to Day 11.
Cmax	To examine the effect on the PK profiles of laroprovstat and rosuvastatin when administered as an FCDP test formulation 1 with high fat meal compared to when administered as an FCDP test formulation 1 in the fasted state.	At predefined intervals form Day 1 to Day 11
tmax	To examine the effect on the PK profiles of laroprovstat and rosuvastatin when administered as an FCDP test formulation 1 with high fat meal compared to when administered as an FCDP test formulation 1 in the fasted state.	At predefined intervals from Day 1 to Day 11
λz	To examine the effect on the PK profiles of laroprovstat and rosuvastatin when administered as an FCDP test formulation 1 with high fat meal compared to when administered as an FCDP test formulation 1 in the fasted state.	At predefined intervals form Day 1 to Day 11
t1/2λz	To examine the effect on the PK profiles of laroprovstat and rosuvastatin when administered as an FCDP test formulation 1 with high fat meal compared to when administered as an FCDP test formulation 1 in the fasted state.	At predefined intervals from Day 1 to Day 11.
CL/F	To examine the effect on the PK profiles of laroprovstat and rosuvastatin when administered as an FCDP test formulation 1 with high fat meal compared to when administered as an FCDP test formulation 1 in the fasted state.	At predefined intervals form Day 1 to Day 11
V/F	To examine the effect on the PK profiles of laroprovstat and rosuvastatin when administered as an FCDP test formulation 1 with high fat meal compared to when administered as an FCDP test formulation 1 in the fasted state.	At predefined intervals from Day 1 to Day 11

Collaborators and Investigators

• Sponsor: AstraZeneca
• Collaborators: Parexel

Publications and helpful links

Helpful Links

• TY card

Study record dates

Study Major Dates

• Study Start (Actual): March 16, 2026
• Primary Completion (Estimated): May 29, 2026
• Study Completion (Estimated): May 29, 2026

Study Registration Dates

• First Submitted: December 19, 2025
• First Submitted That Met QC Criteria: December 19, 2025
• First Posted (Actual): January 5, 2026

Study Record Updates

• Last Update Posted (Actual): May 13, 2026
• Last Update Submitted That Met QC Criteria: May 12, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: Dyslipidemia; Pharmacokinetics; Food effect; Hyperlipidemia; Relative Bioavailability; Fixed combination drug products; Single therapy products; Oral formulations
• Additional Relevant MeSH Terms: Metabolic Diseases; Lipid Metabolism Disorders; Nutritional and Metabolic Diseases; Dyslipidemias; Hyperlipidemias
• Other Study ID Numbers: D7961C00005

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared

• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No